Novartis Expects Clear Demand For Zaditor Following OTC Switch Approval
This article was originally published in The Tan Sheet
Executive Summary
Novartis plans to differentiate its antihistamine eye-drop product Zaditor in the OTC market by positioning the drug as a treatment for the cause, not the symptoms, of itchy eyes
You may also be interested in...
Akorn’s Zatidor generic
FDA grants Akorn approval July 27 for its generic version of Novartis' Zatidor OTC ophthalmic solution (ketotifen fumarate 0.025%), the Buffalo Grove, Ill.-based firm announces in a same-day release. The product, which was approved for OTC use by the agency in October 2006, is indicated for up to 12 hours of relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, Akorn states (1"The Tan Sheet" Oct. 23, 2006, p. 4). The firm estimates Novartis' branded product posted $36 mil. in sales in 2006. The firm plans to launch the product by October, according to the release. Bausch & Lomb has already announced the release of its Zatidor equivalent (2"The Tan Sheet" July 2, 2007, In Brief)...
Akorn’s Zatidor generic
FDA grants Akorn approval July 27 for its generic version of Novartis' Zatidor OTC ophthalmic solution (ketotifen fumarate 0.025%), the Buffalo Grove, Ill.-based firm announces in a same-day release. The product, which was approved for OTC use by the agency in October 2006, is indicated for up to 12 hours of relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, Akorn states (1"The Tan Sheet" Oct. 23, 2006, p. 4). The firm estimates Novartis' branded product posted $36 mil. in sales in 2006. The firm plans to launch the product by October, according to the release. Bausch & Lomb has already announced the release of its Zatidor equivalent (2"The Tan Sheet" July 2, 2007, In Brief)...
Akorn’s Zatidor generic
FDA grants Akorn approval July 27 for its generic version of Novartis' Zatidor OTC ophthalmic solution (ketotifen fumarate 0.025%), the Buffalo Grove, Ill.-based firm announces in a same-day release. The product, which was approved for OTC use by the agency in October 2006, is indicated for up to 12 hours of relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, Akorn states (1"The Tan Sheet" Oct. 23, 2006, p. 4). The firm estimates Novartis' branded product posted $36 mil. in sales in 2006. The firm plans to launch the product by October, according to the release. Bausch & Lomb has already announced the release of its Zatidor equivalent (2"The Tan Sheet" July 2, 2007, In Brief)...